Understanding and targeting resistance mechanisms in cancer

MedComm, Journal Year: 2023, Volume and Issue: 4(3)

Published: May 22, 2023

Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes treatment failure and poor patient survival. The reduced responsiveness cells multifaceted that can arise from genetic, epigenetic, microenvironmental factors. Various mechanisms have discovered extensively studied, including drug inactivation, intracellular accumulation by uptake or increased efflux, target alteration, activation compensatory pathways for cell survival, regulation DNA repair death, tumor plasticity, microenvironments (TMEs). To overcome resistance, variety strategies proposed, are designed enhance effectiveness reduce resistance. These include identifying biomarkers predict response new targets, developing targeted drugs, combination targeting multiple signaling pathways, modulating TME. present article focuses on different resistance corresponding tackling approaches with recent updates. Perspectives polytherapy mechanisms, novel nanoparticle delivery systems, advanced design tools overcoming also reviewed.

Language: Английский

---

Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms

Drug Resistance Updates, Journal Year: 2023, Volume and Issue: 68, P. 100938 - 100938

Published: Feb. 9, 2023

Language: Английский

---

Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101059 - 101059

Published: Jan. 19, 2024

Language: Английский

---

Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 165, P. 115242 - 115242

Published: July 31, 2023

Bladder cancer (BC) is a common and serious type of that ranks among the top ten most prevalent malignancies worldwide. Due to high occurrence rate BC, aggressive nature cells, their resistance medication, managing this disease has become growing challenge in clinical care. Long noncoding RNAs (lncRNAs) are group RNA transcripts do not code for proteins more than 200 nucleotides length. They play significant role controlling cellular pathways molecular interactions during onset, development progression different types cancers. Recent advancements high-throughput gene sequencing technology have led identification various differentially expressed lncRNAs which indicate abnormal expression. In review, we summarize these been found impact several functions related including proliferation, cell growth, migration, metastasis, apoptosis, epithelial-mesenchymal transition, chemo- radio-resistance. Additionally, may improve prognosis prediction BC patients, indicating future use them as prognostic diagnostic biomarkers patients. This review highlights genetic tools anti-tumor agents, such CRISPR/Cas systems, siRNA, shRNA, antisense oligonucleotides, vectors, created preclinical models. interest using based on positive research findings.

Language: Английский

---

Polyphenol-Loaded Nano-carriers for Breast Cancer Therapy: A Comprehensive Review

BioNanoScience, Journal Year: 2024, Volume and Issue: 14(4), P. 4219 - 4237

Published: Jan. 10, 2024

Language: Английский

---

hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: Jan. 7, 2025

Abstract Background Alternative splicing (AS) is a process that facilitates the differential inclusion of exonic sequences from precursor messenger RNAs, significantly enhancing diversity transcriptome and proteome. In cancer, pathogenic AS events are closely related to cancer progression. This study aims investigate role regulatory mechanisms in gastric (GC). Methods We analyzed various tumor samples identified hnRNPU as key factor GC. The effects on progression were assessed through vitro vivo experiments. Gene knockout models FTO inhibitor (meclofenamic acid) used validate interaction between their impact AS. Results found serves GC, its high expression associated with poor clinical prognosis. Genetic depletion reduced GC Mechanistically, m 6 A demethylase interacts transcripts, decreasing modification levels hnRNPU, which leads exon 14 skipping MET gene, thereby promoting meclofenamic acid effectively inhibited cell growth both vivo. Conclusion FTO/hnRNPU axis induces aberrant MET, growth. Targeting may interfere abnormal provide potential diagnostic therapeutic strategy for Graphical Schematic model findings this work: Aberrant binds FTO. A-modified transcripts recognized by reader YTHDF3 subsequently demethylated demethylation enhances stability mRNA, consequently alternative MET. altered pattern ultimately contributes proliferation cells.

Language: Английский

---

Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects

Life Sciences, Journal Year: 2022, Volume and Issue: 309, P. 120984 - 120984

Published: Sept. 20, 2022

Language: Английский

---

CJ₂: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane

Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 66(1), P. 875 - 889

Published: Jan. 3, 2023

Platinum drugs as primary chemotherapy have been applied to various cancer patients. However, their therapeutic applicability is limited due the adverse effects and immunosuppression. To minimize side boost immune response, we designed synthesized platinum(IV) prodrugs that introduced BRD4 inhibitor JQ-1. Among them, CJ2 had most potent activity less toxicity. With introduction of ligand JQ-1, CJ2-reduced PD-L1 protein was found in cytoplasm cytomembrane for first time. By interfering with synthesis, could arouse system promote CD8+ T cell infiltration. Meanwhile, accelerate degradation block DNA damage repair. In vivo, markedly suppressed tumor growth by reversing immunosuppression microenvironment enhancing damage. These findings provide an effective approach improve selectivity platinum elevated response.

Language: Английский

---

Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches

Molecular Omics, Journal Year: 2023, Volume and Issue: 19(4), P. 297 - 307

Published: Jan. 1, 2023

The integration of multi-omics approaches presents new opportunities and challenges for exploring the molecular mechanisms tumor cisplatin resistance.

Language: Английский

---

Tellurium-containing polymers: Recent developments and trends

Progress in Polymer Science, Journal Year: 2023, Volume and Issue: 141, P. 101678 - 101678

Published: April 20, 2023

Language: Английский

---